ARS Pharmaceuticals Inc
NASDAQ:SPRY
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.48
17.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ARS Pharmaceuticals Inc
Wall Street
Price Targets
SPRY Price Targets Summary
ARS Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
SPRY
is 29.58 USD
with a low forecast of 26.26 USD and a high forecast of 36.75 USD.
SPRY Last Price Targets
ARS Pharmaceuticals Inc
The latest public price target was made on Aug 19, 2024 by
Josh Schimmer
from
Cantor Fitzgerald
,
who expects
SPRY
stock to
rise by 168%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Josh Schimmer
Cantor Fitzgerald
|
30
USD
Upside 168% |
4 months ago
Aug 19, 2024
|
ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
TheFly
|
Strong Buy
Raymond James
|
22
USD
Upside 97% |
4 months ago
Aug 12, 2024
|
ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
TheFly
|
|
Ryan Deschner
Raymond James
|
18
USD
Upside 61% |
4 months ago
Jul 25, 2024
|
ARS Pharmaceuticals initiated with an Outperform at Raymond James
TheFly
|
|
Roanna Ruiz
Leerink Partners
|
18
USD
Upside 61% |
9 months ago
Mar 5, 2024
|
Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SPRY's stock price target?
Price Target
29.58
USD
According to Wall Street analysts, the average 1-year price target for
SPRY
is 29.58 USD
with a low forecast of 26.26 USD and a high forecast of 36.75 USD.
What is ARS Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
912%
The
compound annual growth rate
of ARS Pharmaceuticals Inc's revenue for the next 4 years is
912%.
You don't have any saved screeners yet
